Heather Marie Redfearn

Title: Heather Marie Redfearn: Innovator in Cancer Treatment

Introduction

Heather Marie Redfearn is a distinguished inventor based in Macclesfield, GB. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target mutated forms of the epidermal growth factor receptor (EGFR). With a total of 8 patents to her name, her work is pivotal in advancing cancer treatment options.

Latest Patents

Among her latest patents are the 2-(2,4,5-substituted-anilino)pyrimidine compounds. These compounds and their pharmaceutically acceptable salts are designed to treat or prevent diseases mediated by specific mutated forms of EGFR, such as the L858R activating mutant, the Exon19 deletion activating mutant, and the T790M resistance mutant. The invention also encompasses pharmaceutical compositions that include these compounds, particularly useful polymorphic forms, and intermediates for their manufacture. This innovation holds promise for treating various types of cancer.

Career Highlights

Heather has worked with notable companies, including AstraZeneca AB, where she has contributed her expertise in pharmaceutical development. Her work has been instrumental in creating effective treatments for complex medical conditions.

Collaborations

Throughout her career, Heather has collaborated with esteemed colleagues such as Sam Butterworth and Maurice Raymond Verschoyle Finlay. These partnerships have enhanced her research and development efforts in the pharmaceutical industry.

Conclusion

Heather Marie Redfearn's innovative work in developing targeted cancer therapies showcases her commitment to improving medical treatments. Her contributions continue to impact the field of pharmaceuticals positively.